Galectin Therapeutics Reports 2025 Financial Results

The biotech company provided an update on its business and operations.

Mar. 31, 2026 at 1:35pm

Got story updates? Submit your updates here. ›

A photorealistic studio still-life image featuring a stack of medical research papers, a pen, and a glass beaker arranged elegantly on a clean, monochromatic background, conceptually representing the abstract ideas of corporate strategy and pharmaceutical innovation.Galectin Therapeutics' 2025 financial report highlights the company's continued investment in its pipeline of therapies for fibrotic diseases and cancer.Norcross Today

Galectin Therapeutics, a biopharmaceutical company focused on developing therapies for fibrotic diseases and cancer, has reported its financial results for 2025 and provided an update on its business operations and pipeline.

Why it matters

As a publicly traded biotech company, Galectin's financial performance and pipeline progress are closely watched by investors and the broader pharmaceutical industry. The company's focus on fibrotic diseases and cancer represents an important area of unmet medical need.

The details

In its 2025 financial report, Galectin highlighted several key developments, including the continued advancement of its lead drug candidate for the treatment of non-alcoholic steatohepatitis (NASH) and the initiation of a new clinical trial for a cancer immunotherapy. The company also reported an increase in research and development spending as it continues to invest in its pipeline.

  • Galectin Therapeutics reported its 2025 financial results on March 31, 2026.

The players

Galectin Therapeutics, Inc.

A biopharmaceutical company focused on developing therapies for fibrotic diseases and cancer.

Got photos? Submit your photos here. ›

The takeaway

Galectin Therapeutics' 2025 financial results and business update highlight the company's ongoing efforts to advance its pipeline of therapies for fibrotic diseases and cancer, which represent significant areas of unmet medical need. Investors will be closely watching the company's progress as it continues to invest in research and development.